The Wegovy tablet is the first oral GLP-1 receptor agonist indicated for weight loss and cardiovascular risk reduction in eligible adults.

If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.

Early treatment phases may transiently promote immune activation, whereas sustained therapy, by reducing BMI and lowering systemic inflammation, may mitigate this effect.

“Delay in diagnosis will result in delay in amplification, with subsequent delay in language and even cognitive development.” — Julie Wei, MD, Akron Children’s Hospital

“This device will become many patients’ primary epinephrine device because it removes the hurdle to administering epinephrine earlier in the anaphylactic process.” — Haley Overstreet, MD, Aspire Allergy & Sinus

“Today’s approval of the first generic fluticasone propionate inhalation aerosol represents an important step in expanding access to affordable asthma treatment.” – Iilun Murphy, MD, Director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research